Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01510626 · ClinicalTrials.gov registry record · Phase 1
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01510626: Completed Phase 1 study, sponsored by Stanford University.
NCT01510626 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01510626, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The long-term goal of the investigators study is to develop a better and safer treatment for, and to potentially cure patients with single or multiple food allergies. The investigators hypothesize that the application of this protocol will allow patients with severe and single or multiple food allergies to be safely and rapidly desensitized.
Interventions
- DRUG Omalizumab
- DIETARY_SUPPLEMENT Food proteins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
What the finished NCT01510626 record still lists
NCT01510626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 2 interventions - of which Omalizumab is the first listed.
NCT01510626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01510626 about?
NCT01510626 is a clinical study titled "Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center". The long-term goal of the investigators study is to develop a better and safer treatment for, and to potentially cure patients with single or multiple food allergies. The investigators hypothesize that the application of this protocol will allow patients with severe and single or multiple food aller...
What is the current status of trial NCT01510626?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2011-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01510626?
The interventions under investigation include: Omalizumab (DRUG), Food proteins (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01510626?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01510626's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia